Key Developments: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,496.00GBp
17 Apr 2014
Price Change (% chg)

-7.00p (-0.47%)
Prev Close
1,503.00p
Open
1,503.00p
Day's High
1,522.00p
Day's Low
1,496.00p
Volume
391,360
Avg. Vol
257,458
52-wk High
1,699.00p
52-wk Low
893.45p

Search Stocks

Latest Key Developments (Source: Significant Developments)

Hikma Pharmaceuticals PLC announces resolution to US FDA warning letter at Eatontown facility
Wednesday, 2 Apr 2014 02:00am EDT 

Hikma Pharmaceuticals PLC:Receives close-out letter from the US Food and Drug Administration that lifts the warning letter received in Feb. 2012 in respect of its Eatontown facility in New Jersey, which provides oral products for the US market.This communication follows the US FDA's re-inspection of the facility in Feb. to complete its evaluation of the corrective actions taken in response to the warning letter.This resolves all issues raised by the US FDA in Feb. 2012 and all subsequent communications.  Full Article

Hikma Pharmaceuticals PLC declares dividends
Wednesday, 12 Mar 2014 03:00am EDT 

Hikma Pharmaceuticals PLC:Recommends final dividend of 13.0 cents and special final dividend of 4.0 cents per share.To be paid on May 22 to shareholders on register of close of business on Apr 25.Ex-dividend date is on Apr 23.  Full Article

Hikma Pharmaceuticals PLC raises FY 2013 revenue outlook
Friday, 14 Feb 2014 02:00am EST 

Hikma Pharmaceuticals PLC:Expects FY 2013 revenue growth to be around 23 pct, ahead of previous guidance of around 20 pct.The company reported revenue of $1.108 bln in FY 2012.FY 2013 revenue of $1.246 bln -Thomson Reuters I/B/E/S.  Full Article

Hikma Pharmaceuticals Plc announces retirement and appointment of Chairman
Tuesday, 11 Feb 2014 09:22am EST 

Hikma Pharmaceuticals Plc:Says Samih Darwazah, non-executive Chairman, is to retire from the Board and become honorary Life President.Says Said Darwazah, Chief Executive, is to be appointed Chairman and Chief Executive.  Full Article

Hikma Pharmaceuticals Plc Sees To Meet FY 2013 Revenue Guidance
Friday, 8 Nov 2013 02:00am EST 

Hikma Pharmaceuticals Plc announced that for fiscal 2013, it expects to meet the guidance of around 20% revenue growth. The Company reported revenue of $1.108 billion for fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.320 billion for fiscal 2013.  Full Article

Hikma Pharmaceuticals Plc Enters Ethiopian Pharmaceutical Market Through Joint Venture With MIDROC Group
Wednesday, 18 Sep 2013 02:00am EDT 

Hikma Pharmaceuticals Plc announced that it has signed a 50:50 joint venture (JV) agreement with MIDROC Pharmaceuticals Limited, a member of Sheikh Mohammed Hussein Al Amoudi's MIDROC Group (MIDROC), to establish a presence in the Ethiopian pharmaceutical market. The JV will be called HikmaCure. Over the next five years, HikmaCure will establish an Ethiopian operating company, build a local manufacturing facility and will begin marketing and distributing pharmaceutical products in Ethiopia. In the short term, MIDROC will work with Hikma and HikmaCure to register, market and distribute Hikma's products in the Ethiopian market. Hikma and MIDROC will invest in HikmaCure in equal proportions and have committed to provide up to $22.3 million each in cash. The funds will be invested over time and will be used to build and fit-out a local manufacturing and distribution facility in Ethiopia and to provide working capital support for the operations of HikmaCure. The facility is expected to begin commercial production in 2017.  Full Article

Hikma Pharmaceuticals Plc Declares Dividend
Wednesday, 21 Aug 2013 02:00am EDT 

Hikma Pharmaceuticals Plc announced that its Board has declared an interim dividend of 7.0 cents per share (approximately 4.5 pence per share), compared to 6.0 cents per share for the first half of 2012. In addition, the Board has declared a special dividend of 3.0 cents (approximately 1.9 pence per share), which reflects the performance of the Generics business in the first half. The interim dividend and the special dividend will be paid on October 7, 2013 to eligible shareholders on the register at the close of business on September 6, 2013. The ex-dividend date is September 4, 2013 and the final date for currency elections is September 13, 2013.  Full Article

Hikma Pharmaceuticals Plc Raises FY 2013 Revenue Guidance
Wednesday, 21 Aug 2013 02:00am EDT 

Hikma Pharmaceuticals Plc announced that for fiscal 2013, it expects the group to deliver revenue growth of around 20%. The Company reported revenue of $1.108 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.287 billion for fiscal 2013.  Full Article

Hikma Pharmaceuticals Plc Raises FY 2013 Revenue Guidance
Monday, 8 Jul 2013 02:00am EDT 

Hikma Pharmaceuticals Plc announced that it expects group revenue to grow by around 17%, up from the previous guidance of around 13%. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.256 billion for fiscal 2013.  Full Article

Hikma Pharmaceuticals Plc Licenses VIBATIV From Theravance, Inc-Reuters
Monday, 1 Jul 2013 08:00pm EDT 

Reuters reported that Hikma Pharmaceuticals Plc announced the signing of an exclusive commercialisation agreement with Theravance, Inc. for VIBATIV (telavancin) in the Middle East and North Africa (MENA) region. Under the terms of the agreement, Hikma will have the exclusive rights to register, market and distribute VIBATIV in 16 countries across MENA. The agreement will leverage Hikma‚Äôs local presence and regulatory in MENA, with over 1,600 sales and marketing reps across the region.  Full Article

Search Stocks